|  |  |
| --- | --- |
| http://www.e-cancer.fr/images/stories/INCaNet/INCaNet/nouveau-logo-inca_2015.jpg | **[Cliquez ici pour aller sur le site du ministère des Affaires sociales et de la Santé](http://www.solidarite.gouv.fr/)** |

**Appel à projets national en cancérologie 2015**

**Lettre d’intention / *Letter of intent***

**La lettre d’intention est à rédiger en anglais pour permettre l'évaluation internationale**

**Date limite de soumission en ligne : 19 mars 2015 avant Minuit**

**Veuillez cocher l'appel pour lequel vous soumettez votre projet**

|  |  |
| --- | --- |
| **Si soumission PHRC-K :** **□**  **http://www.e-cancer.fr/aap/recherche/phrck2015** | **Si soumission PRME-K :** **□**  **http://www.e-cancer.fr/aap/recherche/prmek2015** |

**In the frame of DGOS calls for proposals:**

First submission **□** Previous submission **□** (fill in section dedicated to previous submission in the last page):

|  |
| --- |
| **Titre de l’étude envisagée, précédé par son acronyme[[1]](#footnote-1)** |
|  |
| **Project title** |
|  |

**GENERAL INFORMATION**

|  |  |
| --- | --- |
| **First name and name of coordinator :** |  |
| Specialty |  |
| Service ou département - Unit or department |  |
| Name and adress of the hospital |  |
| Phone number |  |
| E-mail |  |
| Physician, dental practitioner / Biologist / Nurse, other paramedical : |  |

|  |  |
| --- | --- |
| **Previous grants in the frame of DGOS calls (List with: year, ref number, state.):** |  |

|  |  |
| --- | --- |
| **Research domain**  -Organ, tumor location :  -Others : |  |
| **Keywords**  -Coordinator domain :  -Whished reviewer domain: |  |

|  |  |
| --- | --- |
| **Affiliated institution responsible for the budget from ministry of health** |  |
| **Approximate level of funding required (K euros):** |  |

|  |  |
| --- | --- |
| **First name and name of the methodologist :** |  |
| Name and adress of the hospital |  |
| Phone number |  |
| E-mail |  |
| **First name and name of the economist (if any)** |  |
| Name and address of the establishment: |  |
| Phone number |  |
| E-mail |  |

|  |  |
| --- | --- |
| **Organization responsible for project management:** |  |
| **Organization responsible for quality assurance:** |  |
| **Organization responsible for data management and statistics :** |  |

|  |  |
| --- | --- |
| **Anticipated number of recruiting centers (NC)** |  |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | **Co-investigators (1 à n)** | | | | | | | |
| N° | Name | | Firstname | Town | Country | Hospital | E-mail | Tel | Speciality |
| 1 |  | |  |  |  |  |  |  |  |
| 2 |  | |  |  |  |  |  |  |  |
| 3 |  | |  |  |  |  |  |  |  |
| 4 |  | |  |  |  |  |  |  |  |
| 5 |  | |  |  |  |  |  |  |  |

|  |
| --- |
| **References** |
| *List of the main publications (5 maximum) justifying the project in the national and international context*  - 1  - 2  - 3  - 4  - 5 |

**RESEARCH PROJECT**

|  |
| --- |
| **Rational (Context and hypothesis, max 320 words)** |
|  |
| **Originality and innovative aspects (max 160 words)** |
|  |
| **Focus of research** |
| Health technology (tick and then detail):  Drugs □ Devices □  Procedures and organizational systems used in health care (including Health services*[[2]](#footnote-2)*) □  If relevant: date of CE mark / market authorization  **Please detail :** |
| **Keywords (5):** |
|  |
| **Main objective (Detail, max 48 words)** |
|  |

|  |
| --- |
| **Tick one:** |
| Hypothesis □ Description feasibility □ Tolerance efficacy □  Safety efficience □ Budget impact □ Organization of care □ |
| **Tick one:** |
| Etiology Causality[[3]](#footnote-3)□ Diagnosis □ Prognosis □  Therapeutics (impact on clinical end-points[[4]](#footnote-4) ) □  Therapeutics (impact on intermediate end-point[[5]](#footnote-5) ) □  Compliance □ Effective Practice □ Research methodology □  Qualitative Research □ Others□ |

|  |
| --- |
| **Secondary objectives (detail, max 160 words)** |
|  |
| **Primary end point (linked with the main objective)** |
|  |
| **Secondary end points (linked with the secondary objectives)** |
|  |
| **Study population** |
| **Main inclusion and exclusion criteria** |

|  |
| --- |
| **Design (tick + detail max 320 words)** |
| Meta analysis □ Randomized clinical trial □ if yes : Open □ Single blind □ Double blind□  Systematic reviews □ Pragmatic studies □  Quasi-experimental studies (non randomized cohorts …) □ Prospective cohort study □  Case-control study □ Cross-sectional study □  Retrospective cohort □ Administrative / hospital inpatient database research □  Modelisation □ Case series □ Qualitative studies□ Others □  **Please detail :** |

|  |
| --- |
| **If health-economics analysis (tick + detail max 320 words) :** |
| Cost-utility analysis □ Cost-effectiveness analysis □ Cost-benefit analysis □  Budget impact analysis□ Cost-minimization analysis □ Cost-consequence analysis□  Cost of illness analysis □ Others □  **Please detail :** |
| **In the case of a drug trial:** |
| **Phase: I □ phase: II □ phase: I/II □ phase: III □ phase: IV □** |
| **If comparison groups :** |
|  |
| **Experimental group (detail max 48 words)** |
|  |
| **Control group (detail max 48 words)** |
|  |

**INCLUSIONS**

|  |
| --- |
| **Duration of participation of each patient (days/months/years):** |
|  |
| **Anticipated duration of recruitment (DUR) (in months):** |
|  |
| **Total number of scheduled patients / observations to be recruited (NP) (3 digits + Justification of sample size max 80 words):** |
|  |

|  |
| --- |
| **Number of patients / observations to be recruited / month / center ((NP/DUR)/NC) (2 digits + Justification if more than 2 patients/month/center)** |
|  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Expected number of patients eligible in the centers** | | | | | | |
| N° | Name | Surname | Town | Country | Expected recruitment/month | Total |
| 1 |  |  |  |  |  |  |
| 2 |  |  |  |  |  |  |
| 3 |  |  |  |  |  |  |
| 4 |  |  |  |  |  |  |
| 5 |  |  |  |  |  |  |

|  |
| --- |
| **Participation of a research network (Detail max 32 words)** |
|  |
| **Participation of industry (Detail max 64 words)** |
|  |
| **Others aspects to insure the feasibility of the project (Detail max 64 words)** |
|  |
| **Expected patient or public health benefit (Detail max 320 words)** |
|  |

|  |
| --- |
| **In the case of a previous submission, mention the additional aspects relevant to the recommendations of the scientific committee (Experts comments and corresponding answers, max 320 words)** |
|  |

1. L’acronyme sera formé d’un nombre de lettres inférieur à 15, suivi de 2 chiffres (01 le plus souvent, ou 02 s’il s’agit du 2ème projet dans la continuation d’un 1er projet portant le même titre, etc… [↑](#footnote-ref-1)
2. http://htaglossary.net [↑](#footnote-ref-2)
3. Studies designed to determine the causes of a disease, the risk of being exposed to a drug, a pollutant etc [↑](#footnote-ref-3)
4. Example : reduction of myocardial infarction incidence, of mortality [↑](#footnote-ref-4)
5. Example : reduction of serum cholesterol, improvement of a pain scale [↑](#footnote-ref-5)